AgingResearch.NewsJoin free

ELA-32

ELA-32 has been studied in 1 paper since 2024: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Nov 20, 2024: “Elabela alleviates cuproptosis and vascular calcification in vitaminD3- overloaded mice via regulation of the PPAR-γ /FDX1 signaling”.

Intervention

1 paper studies it1 findingUpdated

PubChem

More peptides

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

  • 1 lab in 1 country
  • Funders: Beijing Natural Science Foundation and 1 more
  • Animals1

What did studies of ELA-32 find?

1

Studies of ELA-32 measured 1 outcome; the most studied are vascular calcification (1 study).

Vascular calcification

downin mice1

1 study

  1. ELA-32 protects against vascular calcification in mice.

    “administration of Elabela effectively hindered the progression of vascular cuproptosis and arterial calcification in VitD3-overloaded mice and rat arterial rings models”

    Animalsin VitD3-overloaded mice1 mg/kg/d

    Elabela alleviates cuproptosis and vascular calcification in vitaminD3- overloaded mice via regulation of the PPAR-γ /FDX1 signaling

    Molecular medicine (Cambridge, Mass.)

More on Vascular calcification

Latest

Related